Nguyen, Alexandra
Mustafa, Al-Hassan M.
Leydecker, Alessa K.
Halilovic, Melisa
Murr, Janine
Butter, Falk
Krämer, Oliver H.
Funding for this research was provided by:
Wilhelm-Sander Foundation (2019.086.1)
Brigitte und Dr. Konstanze-Wegener-Stiftung
German Research Foundation/Deutsche Forschungsgemeinschaft (KR2291)
Walter Schulz Stiftung
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 11 November 2023
Accepted: 26 March 2024
First Online: 3 April 2024
Declarations
:
: Not applicable.
: All authors have read the manuscript and agree with its publication.
: O.H.K. declares the patents “The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity, WO/2004/027418”, “Novel HDAC6 inhibitors and their uses, WO2016020369A1”, and “Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, WO2019/034538”, and paid advisory consultant activity for BASF, Ludwigshafen, Germany. The substances that are covered in these patents are not those that are shown in the submitted manuscript and the BASF had no influence on this study. Thus, there are no direct competing interests. All other authors declare that they have no conflict of interest.